2020 EACR Liquid Biopsies Sponsored Symposia

NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics

Erin Newburn, PhD
Associate Director, Field Applications Scientist
Dan Norton
Dan Norton, MBA
Sr. Product Manager

NeXT Liquid Biopsy™, a first-of-its-kind, high-performance exome-wide liquid biopsy assay, is designed to complement ImmunoID NeXT™, providing a unique ability to evaluate the cancer ecosystem, and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and the blood.  NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.